The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours
Official Title: A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTINÔ), in Patients With Advanced Solid Tumours
Study ID: NCT00750425
Brief Summary: Phase I, open study to assess the effect of ketoconazole, a marketed drug, on the way the body handles the experimental drug cediranib, in patients with advanced cancer.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, Hamilton, , Canada
Research Site, Toronto, , Canada
Research Site, Vancouver, , Canada
Research Site, Herlev, , Denmark
Research Site, Kobenhavn, , Denmark
Name: Jane Roberston
Affiliation: AstraZeneca Aderley Park
Role: STUDY_DIRECTOR
Name: Dr U Lassen, MD PhD
Affiliation: The Finsen Center, Copenhagen, Denmark
Role: PRINCIPAL_INVESTIGATOR